It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.
Avacta's Alastair Smith updates on selection of cancer candidate to take into clinic
Quick facts: Avacta Group PLC
Price: 17.25 GBX
Market Cap: £20.04 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE